Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO6926496 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | 8 volunteers (6 active, 2 placebo) |
| Cohort 2 | EXPERIMENTAL | 8 volunteers (6 active, 2 placebo) |
| Cohort 3 | EXPERIMENTAL | 8 volunteers (6 active, 2 placebo) |
| Cohort 4 | EXPERIMENTAL | 8 volunteers (6 active, 2 placebo) |
| Cohort 5 | EXPERIMENTAL | 8 volunteers (6 active, 2 placebo) |
| Cohort 6 | EXPERIMENTAL | 8 volunteers (6 active, 2 placebo) |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Matching placebo to RO6926496 |
| RO6926496 | DRUG | single, ascending dose, intravenous administration |
Inclusion Criteria: * Healthy male participants, 18 to 45 years of age; healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history * A body mass index between 18 and 30 kg/m2 * Male subjects and their partners of childbearing ...
RO6926496 is an investigational small molecule developed by Roche Holding AG. It has been studied in a Phase 1 clinical trial in healthy adult male volunteers in the United Kingdom. The specific disease or condition it is intended to treat has not been publicly disclosed, and it remains in early clinical development.
RO6926496 is being developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the clinical program for this investigational small molecule.
RO6926496 is in Phase 1 clinical development. Its only recorded trial, NCT02281786, was a Phase 1 study in healthy volunteers that has been completed. The drug is investigational and has not been approved by the FDA for any indication.
RO6926496 has been evaluated in one clinical trial, NCT02281786, titled A Study of RO6926496 in Healthy Volunteers. The Phase 1 trial enrolled 48 participants in the United Kingdom, was randomized, double-blind, and controlled, and is now completed. No active trials are currently listed.
The therapeutic use of RO6926496 has not been publicly disclosed. Its completed Phase 1 trial, NCT02281786, was conducted in healthy adult male volunteers rather than in patients with a specific disease, which is typical for early-stage safety and tolerability studies of an investigational small molecule.
The Phase 1 trial of RO6926496, NCT02281786, was a randomized, double-blind, controlled study conducted in the United Kingdom. It enrolled 48 healthy male volunteers aged 18 years and older. The study has been completed, and no biomarker-based patient selection was used.